Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Maintenance chemotherapy: an evolving and increasingly acceptable strategy in cancer management.

Literature DB >> 20711821

Maintenance chemotherapy: an evolving and increasingly acceptable strategy in cancer management.

Abstract

Individual randomized phase 3 trials and meta-analyses of previously published studies have provided support for the general concept of the clinical utility of extending the duration of antineoplastic drug therapy in an effort to prolong ("maintain") a favorable clinical state. This commentary briefly reviews data from several of these reports.

Entities: Disease

Mesh：

Substances：
Antineoplastic Agents

Year: 2010 PMID： 20711821 DOI： 10.1007/s11912-010-0121-4

Source DB: PubMed Journal: Curr Oncol Rep ISSN： 1523-3790 Impact factor: 5.075

22 in total

Review 1. Does maintenance/consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)? A metaanalysis of the published controlled trials.

Authors: Hakan Bozcuk; Mehmet Artac; Mustafa Ozdogan; Burhan Savas
Journal: Cancer Date: 2005-12-15 Impact factor: 6.860

Review 2. Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials.

Authors: Yu Yang Soon; Martin R Stockler; Lisa M Askie; Michael J Boyer
Journal: J Clin Oncol Date: 2009-05-26 Impact factor: 44.544

3. Maintenance therapy for advanced non-small cell lung cancer: current status, controversies, and emerging consensus.

Authors: Taofeek K Owonikoko; Suresh S Ramalingam; Chandra P Belani
Journal: Clin Cancer Res Date: 2010-04-13 Impact factor: 12.531

4. Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer.

Authors: Robert A Burger; Mark F Brady; Joon Rhee; Mika A Sovak; George Kong; Hoa P Nguyen; Michael A Bookman
Journal: Gynecol Oncol Date: 2013-07-29 Impact factor: 5.482

5. Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial.

Authors: Maurie Markman; P Y Liu; James Moon; Bradley J Monk; Larry Copeland; Sharon Wilczynski; David Alberts
Journal: Gynecol Oncol Date: 2009-05-17 Impact factor: 5.482

6. Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group.

Authors: Mahesh A Varia; Frederick B Stehman; Brian N Bundy; Jo Ann Benda; Daniel L Clarke-Pearson; Ronald D Alvarez; Harry J Long
Journal: J Clin Oncol Date: 2003-08-01 Impact factor: 44.544

7. Risk of leukemia after platinum-based chemotherapy for ovarian cancer.

Authors: L B Travis; E J Holowaty; K Bergfeldt; C F Lynch; B A Kohler; T Wiklund; R E Curtis; P Hall; M Andersson; E Pukkala; J Sturgeon; M Stovall
Journal: N Engl J Med Date: 1999-02-04 Impact factor: 91.245

8. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association.

Authors: H B Muss; L D Case; F Richards; D R White; M R Cooper; J M Cruz; B L Powell; C L Spurr; R L Capizzi
Journal: N Engl J Med Date: 1991-11-07 Impact factor: 91.245

Maintenance chemotherapy: an evolving and increasingly acceptable strategy in cancer management.

Review 1. Does maintenance/consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)? A metaanalysis of the published controlled trials.

Review 2. Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials.

3. Maintenance therapy for advanced non-small cell lung cancer: current status, controversies, and emerging consensus.

4. Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer.

5. Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial.

6. Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group.

7. Risk of leukemia after platinum-based chemotherapy for ovarian cancer.

8. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association.

9. Second malignant neoplasms among long-term survivors of ovarian cancer.

10. A case of chronic paclitaxel administration in ovarian cancer.

Review 1. Latest research and treatment of advanced-stage epithelial ovarian cancer.

Review 2. Ovarian cancer treatment: The end of empiricism?